Lisata Therapeutics Inc (LSTA)

[whirlybird]

Two P3 trials using PCT stem cells are nearing completion.
These are the Baxter RENEW and Cardio3 trials in the U.S. and Europe respectively.

The results of the RENEW trial are expected around June of this year. Positive RENEW results should have more clinical significance than positive results from the PreSERVE trial by NBS since they would be P3 results rather than P2 results.

The Mayo Clinic has conducted studies using Cardio3 technology that in turn employs PCT stem cells. "It's critical that this new process of cardiopoiesis was achieved in 100 percent of cases, with a very good safety profile," Dr. Terzic one Mayo researcher said. 100% of cases seems an outstanding result to me.

Even if the PreSERVE trial results are negative, the P3 RENEW results are likely to be positive.